Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
SWIFT, a cluster-randomised registry-based trial (ACTRN 12620001061921) among haemodialysis patients in Australia, tested the effect of a systematic symptom monitoring intervention versus standard care, on health-related quality of life, measured by the EQ-5D-5L, and the SONG-HD fatigue score. The intervention comprised 3-monthly symptom assessment using the IPOS-Renal patient-reported outcome measure, with feedback of symptom scores and evidence-based guidance for symptom management to clinicians. The trial completed recruitment in July 2025 and is in follow-up.
We present baseline characteristics of participating dialysis units and individuals by allocation, including health-related quality of life (utility) and symptom burden on a 5-point scale (none, slight, moderate, severe, overwhelming).
Of 183 units from ANZDATA that were randomised in 94 groups, 92 units participated (n=52 intervention, n=40 standard care), enrolling 2412 participants (n=1378 intervention, n=1034 control), representing ~37% of all satellite haemodialysis patients in participating jurisdictions. The 92 dialysis units were spread across 4 Australian states: New South Wales (22%), Queensland (27%), Victoria (34%), South Australia (17%); with 50 units in metropolitan, 42 in rural areas; 56 public, 36 private; and 18 (20%) with previous IPOS-Renal use. Participants’ median age was 68 years; 38% females; 8% First Nations; 65% Australian-born, 13% European-born, 37% resided in the lowest 3 socio-economic areas. Primary kidney disease was diabetes (39%), glomerular disease (20%), and hypertension (14%); comorbid conditions included diabetes (54%), coronary artery disease (46%), PVD (25%), CVD (15%), similar for both groups. Median BMI was 29 kg/m2; previous kidney transplant was 10%; and median dialysis vintage was 3.8 years. 93% of participants dialysed 3x/week for 4-4.5 hours per session; 80% of participants dialysed with a native fistula. Median dialysis adequacy (urea reduction ratio) was 72% (IQR 64-78).
Mean utility was 0.8056 (SD 0.2354) for intervention and 0.7867 (0.2509) for standard care participants, with 40% reporting a utility of 1.0.
684 of 1,378 intervention participants (50%) reported at least one severe or overwhelming symptom at baseline. The most frequently reported moderate, severe or overwhelming symptoms were: weakness or lack of energy in 687 (50%) participants, difficulty sleeping in 568 (41%), and pain in 530 (38%) participants.
SWIFT is the largest haemodialysis trial in Australia, with participants nationally representative for age, sex, comorbid conditions and haemodialysis vintage. The results highlight a significant symptom burden in the Australian dialysis population. These data will inform clinicians and health services to improve processes of symptom assessment and management including the feasibility and benefits of electronic collection of patient-reported measures using a clinical quality registry. Trial follow-up will be completed in July 2026.
